Loxan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loxan

What is Loxan? A Foundational Overview

Property Description
Active Ingredient Ciprofloxacin (typically as the hydrochloride salt)
Forms Tablets, Solution for Infusion, Eye Drops, Ear Drops
Pharmacological Class Fluoroquinolone Antibiotic (Second Generation)
General Purpose Treatment of Systemic and Local Bacterial Infections
Origin Synthetic Compound

Loxan is the trade designation for a medicinal product featuring the active ingredient Ciprofloxacin, a purely synthetic compound manufactured through chemical processes. Pharmacologically, it is defined as a potent broad-spectrum antibiotic and anti-infective belonging specifically to the fluoroquinolone class of drugs. This classification places it among agents that are clinically recognized for their ability to combat a wide array of bacterial pathogens, distinguishing them within the field of antimicrobial pharmacology.

Ciprofloxacin: Composition, Forms, and Differentiation

The core composition of Loxan utilizes Ciprofloxacin as the sole active ingredient, making it a single-agent product or monotherapy. This compound is a prescription-only medicine (Rx), reflecting its strong, targeted action. The versatility of Ciprofloxacin is a key differentiating factor; it is available in multiple pharmaceutical preparations, including oral tablets, a sterile solution for infusion for systemic delivery, and specialized topical forms like eye drops and ear drops for localized application.

General Function of this Anti-infective Drug

The function of this anti-infective is to provide a robust bactericidal defense. Pharmacological studies consistently demonstrate that Ciprofloxacin achieves this by interfering with the bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for the replication and repair of the bacteria's nucleic acids. This action is designed to cause the rapid and irreversible death of the bacterial cells. The overall purpose of Loxan is to effectively address and resolve the underlying bacterial cause of disease, achieving the general therapeutic goal of clearing systemic bacterial infections and local bacterial loads through targeted elimination.

Regulatory References

  1. Ciprofloxacin Classification (NIH/NCBI)

What side effects are possible with Loxan?

Possible Side Effects and Safety Information

Loxan (Ciprofloxacin) is associated with a range of possible side effects that are formally classified by government regulatory authorities based on their reported frequency in clinical use. These adverse reactions are grouped according to the specific physiological systems they affect, reflecting the drug’s official safety profile.


Frequency-Classified Adverse Reactions

The most Common side effects documented in official labeling include nausea and diarrhea. Effects classified as Uncommon may involve headache, dizziness, abdominal pain, insomnia, restlessness, rash, and transient increases in liver enzymes or kidney parameters. Events designated as Rare include tendinitis, pseudomembranous colitis, and QT interval prolongation.

Serious Adverse Reactions and Safety Constraints

The regulatory label identifies specific reactions as serious, rare, and potentially permanent. These include tendon rupture, most frequently affecting the Achilles tendon, and peripheral neuropathy, which involves symptoms like numbness or tingling. These serious events have been documented to occur not only during treatment but also up to several months after discontinuation of the medicine [FDA Prescribing Information].

Safety constraints noted in regulatory documents include contraindications for individuals with a history of hypersensitivity to quinolones or pre-existing tendinitis associated with this class of drugs. Older adults are noted to be at an increased risk of specific serious adverse reactions, such as tendon rupture and QT interval prolongation [EMA SmPC]. Additionally, the use of Ciprofloxacin in pediatric patients is restricted due to concerns over arthropathy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Loxan

Overdose Scope

Element Official Regulatory Description
Documented overdose presentations: Includes risks for reversible renal toxicity and the physiological finding of crystalluria.
Physiological systems affected (as stated in label): Primarily the Central Nervous System (CNS) and the Cardiovascular system, in addition to the Renal and Urinary system.
Dose-related or exposure-related factors (if applicable): Acute overdosage is associated with documented exposures, including one instance involving 12 g of the oral formulation.
Population-specific overdose notes (if applicable): Patients with pre-existing renal impairment require special consideration due to slower elimination.
Emergency-response statements (as written in official documents): Management procedures include gastric lavage and administration of activated charcoal for recent oral overdosage. Symptomatic and supportive treatment is mandated.
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention or contact a Poison Control Center or emergency room at once upon suspected overdosage.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Description
Severity classification (as defined in official documents): Overdosage can lead to severe, life-threatening outcomes, including seizures and QT interval prolongation.
Regulatory basis (EMA / FDA / etc.): Information is derived from official FDA Prescribing Information and EMA SmPC documents.
Overdose-context constraints (as defined in official documents): The official management protocol specifies that no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Suspected overdose requires seeking immediate medical attention or contacting a Poison Control Center or emergency room at once.
  • Documented manifestations of acute, massive overdosage include risks of reversible renal toxicity and the development of crystalluria.
  • Overdosage can result in the intensification of adverse effects, including CNS effects (e.g., seizures and confusion) and the serious cardiac risk of QT interval prolongation.
  • Management involves symptomatic and supportive treatment, gastric lavage, and the administration of activated charcoal to reduce absorption, given that no specific antidote is known.
  • Maintenance of adequate hydration is required to mitigate the risk of crystalluria, and monitoring of renal function and the ECG is necessary.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Loxan overdose profile by documenting the potential for toxicity across major physiological systems, including the CNS, cardiovascular, and renal systems. The profile mandates the immediate cessation of the drug and the seeking of urgent medical help as the primary response. The required management is non-specific, focusing on supportive measures and close monitoring due to the absence of a specific antidote listed in the official labeling.

Therapeutic Uses of Loxan

What Loxan Treats: Main Uses and Benefits

Loxan (Ciprofloxacin) is used to provide therapeutic support by addressing bacterial pathogens responsible for a range of acute, often complicated, infections. Its application is relevant in contexts involving heightened systemic burden, aiming to manage the infection and may assist with reducing patient distress. This medication is commonly used across multiple critical therapeutic domains.


Therapeutic Scope and Symptom Management

This medication is relevant in clinical settings marked by heightened distress from severe bacterial infections, particularly in the urinary tract (acute pyelonephritis), deep infections of the bone and joints (osteomyelitis), and critical systemic conditions like typhoid fever or plague. It is also applied in contexts where pronounced symptoms from gastrointestinal or respiratory infections, such as persistent diarrhea or lower respiratory distress, are applied when symptoms create noticeable functional strain.

It helps address symptom clusters that may appear suddenly and intensify over time, including fever, localized pain, and systemic malaise. Loxan is commonly used in situations involving certain distressing symptoms where relevant when supportive symptom management is appropriate.


Quick Fact: Relief for Severe Infection Symptoms

Symptom Management Contributes to easing the overall symptom load by addressing bacterial pathogens across domains involving acute or disruptive symptom patterns.
Condition Focus Commonly used to help with symptoms related to systemic imbalance and localized pain in conditions like complicated UTIs, bone, and certain life-threatening infections.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Loxan (Ciprofloxacin) eligibility is strictly defined by regulatory criteria regarding patient characteristics and existing conditions. The medication is contraindicated and must not be used in patients with a known history of hypersensitivity to ciprofloxacin, to other quinolone antibiotics, or to any of its inactive components. Co-administration with the drug tizanidine is also an absolute contraindication as specified in the official labeling.

Adults are the standard eligible population for most uses. However, pediatric use (children and adolescents) is heavily restricted and generally not recommended for common or mild infections. Use in children is reserved only for a limited number of severe infections, such as anthrax, plague, or complicated urinary tract infections, as documented by regulatory bodies.

Use is conditional and requires special caution or avoidance in several populations. Patients with a known history of myasthenia gravis or certain cardiac risk factors, such as QT interval prolongation, should avoid the medicine. Those with reduced renal function or impaired hepatic function are eligible but require careful management as per official prescribing information. Additionally, regulatory documents state that use in lactating women is not recommended, and the medicine is contraindicated during pregnancy in some regions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Loxapine, the active ingredient in Loxan, has documented interactions primarily relating to its effects on the central nervous system (CNS) and its impact on certain cardiovascular agents.

Product Category Interaction Mechanism and Effect
CNS Depressants (e.g., alcohol, sedatives, narcotics) Additive CNS depression, which can severely increase effects such as drowsiness, sedation, or impaired concentration. Co-administration in severe drug-induced depressed states is contraindicated (must not be used).
Epinephrine (Adrenaline) Loxapine inhibits the vasopressor (blood pressure raising) effect of epinephrine. If severe hypotension occurs, alternative vasopressor agents like norepinephrine or angiotensin are the preferred treatment options.
Anticholinergic Agents (e.g., certain antiparkinson medications) Additive anticholinergic effects, which may worsen side effects such as dry mouth, constipation, blurred vision, and difficulty urinating, requiring cautious use.

Loxapine lowers the convulsive threshold, increasing the risk of seizures. Patients with a history of convulsive disorders require extreme caution and careful monitoring when using this medication. In all cases, individuals should disclose all prescription and non-prescription medicines, supplements, and alcohol use to their healthcare provider to manage these potential interactions.

Mechanism of Action

How Loxan Works

Loxan's mechanism is defined by the action that directly inactivates the bacterial enzymes responsible for maintaining genetic integrity. The resulting physiological effect is the irreversible termination of the bacterial cell.


Targeting Bacterial DNA Management Enzymes

This domain covers the primary molecular interaction of the drug: the selective binding to and poisoning of two essential bacterial enzymes, DNA Gyrase and Topoisomerase IV. These Type II Topoisomerases are critical for bacterial DNA replication, transcription, and chromosome separation.


Initiating the Lethal DNA Damage Cascade

By binding to the enzyme-DNA complex, the drug blocks the final step of DNA repair and resealing, functioning as an enzyme poison. This stabilization rapidly generates overwhelming double-stranded DNA breaks (DSBs), physically arresting all essential genetic processes. This cascade results in the bactericidal effect.


️ Mechanistic Limitations

The drug's mechanism is constrained by bacterial evolution, particularly mutations in the target genes (gyrA and parC) that reduce binding affinity. Furthermore, the over-expression of efflux pumps actively reduces the necessary intracellular concentration of the drug, thus preventing the initiation of the lethal DNA damage cascade.

Dosage and Administration Information

How to Use Loxan (Ciprofloxacin): Official Administration Guidelines

Loxan (Ciprofloxacin) is administered according to strict official protocols governing its route, frequency, duration, and patient-specific adjustments. This ensures the medicine is used in a standardized manner.

Administration Routes and Standard Frequency

Ciprofloxacin is available for systemic delivery via Oral administration (tablets, extended-release tablets, and suspension) and Intravenous (IV) Infusion. For most systemic infections, the medication is taken twice daily (every 12 hours). The Extended-Release (XR) tablets, however, are administered once daily.

Dosing and Treatment Duration

Standard adult oral doses typically range from 250 mg to 750 mg per dose. Intravenous doses range from 200 mg to 400 mg per dose. Treatment duration varies significantly by indication, ranging from 3 to 7 days for uncomplicated acute infections to 4 to 8 weeks for deep-seated conditions like bone and joint infections. A specific course of 60 days is prescribed for post-exposure inhalational anthrax.

Specific Administration Conditions

Condition Instruction from Official Labeling
With Food May be taken with or without food.
IV Infusion Must be administered slowly over a period of 60 minutes.
Drug Form Integrity Extended-Release tablets must be swallowed whole; they must not be crushed, split, or chewed.
Cation Timing Oral administration should be separated by at least 2 hours before or 6 hours after taking multivalent cation-containing products (e.g., antacids, iron supplements).

Population-Specific Adjustments

Official instructions require that the dosage be reduced or the interval extended for patients with renal impairment, based on their measured creatinine clearance. For pediatric patients, dosing is based on body weight for approved indications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Loxan

Evidence for Use in Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (APN)

Research on Loxan for complicated UTIs and acute pyelonephritis (a kidney infection) primarily involves short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing Loxan to other antimicrobials that were studied at the time. The studies monitored specific outcomes related to bacteriological eradication (clearing the harmful bacteria) and clinical cure (the resolution of acute signs such as fever). The findings describe patterns observed in the studies, often reporting measurements of pathogen clearance at the end of the treatment period. Comparative research often reported that Loxan performed similarly to the studied comparator treatments on these endpoints.

Evidence for Use in Bone and Joint Infections

Due to the complex nature of bone infections (such as osteomyelitis), the research explored is often based on Observational Cohort Studies and open-label clinical trials rather than large comparative RCTs. These studies were applied in studies examining patient-reported experiences over long periods, with researchers examining endpoints related to bacteriological clearance and measurements related to the achievement of pre-defined clinical endpoints. Reports described how symptoms evolved in the observed populations over time. The evidence base available includes studies with variable designs, reflecting a reliance on non-RCT designs.

Research Gaps and Remaining Uncertainties

A primary area of uncertainty documented in the research relates to the rapid global emergence of bacterial resistance to fluoroquinolones. This means that older studies, even high-quality RCTs, may not fully capture the data observed in current healthcare settings where resistant strains are prevalent. Additionally, long-term effects are not fully established across all indications, and there is limited information for outcomes reflecting daily functioning over extended periods. The findings describe group patterns, but data comparing Loxan to other treatments in many specific subgroups are still emerging.

Frequently Asked Questions (FAQ)

Common questions about Loxan (FAQ)


Q: What is the main reason Loxan is prescribed?

Loxan (Ciprofloxacin) is a broad-spectrum antibiotic. Official information indicates it is approved to treat many types of bacterial infections. These uses are described to include specific infections of the urinary tract, lower respiratory tract, skin, bone, and joints.


Q: Are there any specific foods or drinks to avoid while using Loxan?

Official administration guidelines indicate Loxan tablets should not be taken with dairy products, such as milk or yogurt, and mineral-fortified fruit juices (e.g., calcium-fortified orange juice). These beverages can significantly reduce the amount of the medicine absorbed by the body.


Q: Can older adults generally use Loxan?

Yes, older adults are generally eligible for Loxan use. Regulatory documents note that the concentration of the medicine in the body can be higher in this age group compared to younger adults due to changes in kidney function. Official guidance indicates that dose modification may be required.


Q: Is it normal to feel [vague side effect, e.g., tired] after starting Loxan?

Loxan is not typically known to cause common fatigue or tiredness. However, some central nervous system side effects have been reported in official labeling, such as dizziness or confusion, which may cause a person to feel generally unwell or 'out of sorts.'


Q: Can Loxan be crushed or split?

The extended-release tablet forms of Loxan must be swallowed whole and should never be crushed, split, or chewed, as this affects the way the medicine is released. Standard tablets are also generally intended to be swallowed whole.


Q: Does Loxan affect laboratory test results?

Yes, official safety information indicates that Loxan has been associated with transient (temporary) changes in certain laboratory tests. These uncommon changes include abnormal results for liver enzymes and kidney parameters.


Q: Are there any special instructions for administering Loxan to someone who can't swallow pills?

Loxan is available as an oral suspension (liquid form) that can be used as an alternative to tablets. Regulatory information specifies that the suspension form is not indicated for administration via nasogastric or feeding tubes.


Q: How long does Loxan stay in your system after taking it?

According to official pharmacokinetic information, Loxan has an elimination half-life of approximately 4 hours in adults with normal kidney function. This indicates the medicine is generally cleared from the body within about 20 to 24 hours after the last dose.


Q: Can I take Loxan if I also take over-the-counter pain relievers?

Official drug interaction information generally shows no significant interaction between Ciprofloxacin and acetaminophen (a common over-the-counter pain reliever). However, regulatory information emphasizes the importance of disclosing all prescription and non-prescription products.


Q: Is Loxan a controlled substance?

Loxan (Ciprofloxacin) is defined as a prescription-only medicine (Rx). According to regulatory classification data, it is not listed as a federally controlled substance.


Q: Does Loxan interact with birth control pills?

Some official drug interaction warnings indicate that Ciprofloxacin may reduce the effectiveness of hormonal birth control containing ethinyl estradiol in some women. This is described as potentially increasing the risk of pregnancy or breakthrough bleeding.


Q: Can Loxan affect my ability to drive or operate machinery?

Official warnings state that Loxan can cause central nervous system side effects such as dizziness, lightheadedness, and nervousness. Because of these effects, performing skilled tasks like driving or operating machinery may be impaired.


Q: Is there a generic version of Loxan available?

Yes. According to the FDA and other regulatory records, generic versions of Loxan (Ciprofloxacin) tablets and oral suspension have been approved and are available.


Q: Can Loxan cause mood changes?

Official regulatory warnings state that psychiatric adverse reactions, including anxiety, depression, confusion, and psychosis, may occur. In rare instances, suicidal thoughts have been reported. Official documents advise that awareness of the potential for significant mood changes during treatment is important.


Q: Are there any known interactions between Loxan and herbal supplements?

Specific interactions with most herbal supplements are not detailed in official regulatory labeling. However, Loxan should be separated by several hours from any mineral-containing supplements (like iron, calcium, or zinc) as these can significantly reduce the medicine’s absorption.


Q: How is Loxan typically eliminated from the body?

Official pharmacokinetic information indicates that Loxan is primarily eliminated from the body through the kidneys (the renal route). This clearance process means that dose modification is typically required for patients with reduced kidney function.


Q: Is there an official patient information leaflet for Loxan?

Yes, regulatory guidance requires that a Patient Information Leaflet (PIL) or Medication Guide be provided with the product at the time of dispensing. This document contains essential official information about the drug's use and safety.


Q: What is the process for reporting a side effect related to Loxan?

Regulatory authorities encourage patients and healthcare professionals to report any suspected side effects or adverse drug reactions. This reporting is done through the official mechanism of your country's regulatory authority, such as the FDA MedWatch program.


Q: What does the term 'contraindication' mean for Loxan?

When a medicine has a contraindication, it means that a specific existing medical condition or circumstance makes the use of Loxan potentially harmful. According to official documents, the medicine is contraindicated under those circumstances.

How should Loxan be stored and disposed of?

Storage and Disposal Requirements for Loxan (Ciprofloxacin)

The storage and disposal of Loxan must follow official requirements to maintain product quality and ensure safety.

Storage Conditions

Loxan tablets must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from intense UV light.

Constraint Requirement
Freezing Do not freeze reconstituted oral suspension.
Child Safety Keep out of reach of children.
Suspension Stability Use reconstituted oral suspension within 14 days.

Disposal Instructions

Unused or expired Loxan should be disposed of through a drug take-back program. If this is unavailable, the product must be mixed with an undesirable substance (e.g., dirt or coffee grounds), placed in a sealed container, and discarded in the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loxan found in:

A-Z Index: